ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

AMRI, Sanofi Settle Fexofenadine Case

by Michael McCoy
November 24, 2008 | APPEARED IN VOLUME 86, ISSUE 47

Albany Molecular Research Inc. and Sanofi-Aventis have settled lawsuits against Barr Pharmaceuticals and Teva Pharmaceutical Industries related to generic versions of fexofenadine HCl, sold by Sanofi as Allegra. Teva and Barr will each pay Sanofi about $30 million plus undisclosed future royalties. AMRI, the contract chemistry research firm that developed the route to the molecule, will get $10 million from Sanofi plus future royalties on fexofenadine products sold by all three firms.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment